DD
44
2
FTI
61
5
WU
26
2
CNX
67
4
MAS
46
3
VRSK
54
2
SNA
56
3
PM
49
8
GRMN
53
3
OXY
42
17
PCG
59
9
GME
61
2
KSS
36
2
HBAN
47
7
R
55
-2
EQT
47
13
CTAS
36
8
DHI
36
3
PLD
35
5
DTE
49
16
DD
44
2
FTI
61
5
WU
26
2
CNX
67
4
MAS
46
3
VRSK
54
2
SNA
56
3
PM
49
8
GRMN
53
3
OXY
42
17
PCG
59
9
GME
61
2
KSS
36
2
HBAN
47
7
R
55
-2
EQT
47
13
CTAS
36
8
DHI
36
3
PLD
35
5
DTE
49
16
Financhill
Back

Krystal Biotech 10K Form

Sell
25

KRYS
Krystal Biotech

Last Price:
$165.06
Seasonality Move:
4.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KRYS News And Ratings

See the #1 stock for the next 7 days that we like better than KRYS

KRYS Financial Statistics

Sales & Book Value

Annual Sales: $50.7M
Cash Flow: $57.8M
Price / Cash Flow: 83.48
Annual Sales: $30.80
Price / Book: 5.35

Profitability

EPS (TTM): 1.78000
Net Income (TTM): $52.4M
Gross Margin: $47.6M
Return on Equity: 6.45%
Return on Assets: 6%

Krystal Biotech Earnings Forecast

Key Krystal Biotech Financial Ratios

  • The Gross Profit Margin over the past 3 years for KRYS is 93.90%.
  • The Selling, General & Administrative Expenses for KRYS have been equal to 194.09% of Gross Profit Margin.
  • The Research & Development expenses have been 91.58% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of KRYS is 21.56% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

Krystal Biotech Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KRYS
CUSIP: 501147
Website: krystalbio.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.97
Quick Ratio: 7.66

Price-to-Earnings

Trailing P/E Ratio: 422.44
Forward P/E Ratio: 24.35

KRYS Technical Analysis vs Fundamental Analysis

Sell
25
Krystal Biotech (KRYS) is a Sell

Is Krystal Biotech a Buy or a Sell?

  • Krystal Biotech stock is rated a Sell
    The current Krystal Biotech [KRYS] share price is $164.75. The Score for KRYS is 25, which is 50% below its historic median score of 50, and infers higher risk than normal.